CLIA

SARS-CoV-2

Ficha producto
Adaptable
Diagnóstico efectivo
Preciso
Seguro

Descripción

CLIA technique is more sensitive that other immunological techniques, which is a great advantage in the rapid and accurate diagnosis of infectious diseases.

Clinically, patients with SARS-CoV-2 infection tend to suffer symptoms such as olfactory and gustatory dysfunction, fever, dry cough, ansomia, fatigue, dyspnoea, headache, diarrhoea and sore throat, followed by vascular and systematic complications. COVID-19 commonly results in pneumoia, which can evolve into acute respiratory distress syndrome, leading to respiratory or multiorgan failure.

On March 11, 2020, the WHO declared the disease a pandemic, due to the high number of infected people and the rapidity of tis spread worldwide.

CerTest CLIA SARS-CoV-2 Ag particles are:

  • Effective and fast. Diagnosis for SARS-CoV-2 will be ready after 15 minutes of reaction.
  • Accurate. CerTest CLIA technology is high accurate, even comparing to high sensitive techniques such as rtPCR.
  • Adaptable to any CLIA analyzer. Flash and Glow reagents are developed for this target, and Bulk format is available under request.

Especificaciones

Formato de ensayo
Chemiluminiscence coated magnetic particles
Método
Quantitative
Tipo de quimioluminiscencia
Flash and Glow, both systems available
Fase sólida y conjugada
High specific monoclonals, developed by CerTest Biotec, S.L.
Etiqueta
HRP and acridinium ester label available
Reactivos
Liquid and stable, ready to use

¿Necesita más información?

CONTACTO